Background:

Y-320 is a new phenylpyrazoleanilide immunomodulator [1].

Immunotherapy refers to treatment of disease by suppressing, inducing or enhancing an immune response.

Y-320 is a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells induced by IL-15 with IC50 values of 20-60 nM [1].

In type II collagen-induced arthritis (CIA) mice, oral administration of Y-320 (0.3-3 mg/kg) reduced IL-17 mRNA expression and significantly inhibited the development of joint destruction and arthritis. The combination of Y-320 with anti-murine tumor necrosis factor-α (TNF-α) monoclonal antibody exhibited a synergistic effect. In cynomolgus monkeys, Y-320 (0.3-1 mg/kg) relieved CIA. These results suggested that Y-320 could be a useful candidate for therapy of rheumatoid arthritis (RA) [1].

Reference:
[1].  Ushio H, Ishibuchi S, Oshita K, et al. A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys. Pharmaceuticals (Basel), 2013, 7(1): 1-17.